Division of Molecular Immunology, German Cancer Research Center, Heidelberg, Germany.
1] Division of Translational Immunology, German Cancer Research Center, Heidelberg, Germany. [2] Regensburg Center for Interventional Immunology, University Clinic and University of Regensburg, Regensburg, Germany.
Nat Immunol. 2015 Jun;16(6):609-17. doi: 10.1038/ni.3159. Epub 2015 Apr 27.
Tumor-associated eosinophilia is frequently observed in cancer. However, despite numerous studies of patients with cancer and mouse models of cancer, it has remained uncertain if eosinophils contribute to tumor immunity or are mere bystander cells. Here we report that activated eosinophils were essential for tumor rejection in the presence of tumor-specific CD8(+) T cells. Tumor-homing eosinophils secreted chemoattractants that guided T cells into the tumor, which resulted in tumor eradication and survival. Activated eosinophils initiated substantial changes in the tumor microenvironment, including macrophage polarization and normalization of the tumor vasculature, which are known to promote tumor rejection. Thus, our study presents a new concept for eosinophils in cancer that may lead to novel therapeutic strategies.
肿瘤相关性嗜酸性粒细胞增多症在癌症中经常观察到。然而,尽管对癌症患者和癌症小鼠模型进行了大量研究,但嗜酸性粒细胞是否有助于肿瘤免疫仍不确定,它们是仅仅是旁观者细胞。在这里,我们报告在存在肿瘤特异性 CD8(+) T 细胞的情况下,活化的嗜酸性粒细胞对于肿瘤排斥是必不可少的。肿瘤归巢的嗜酸性粒细胞分泌趋化因子,引导 T 细胞进入肿瘤,从而导致肿瘤消除和存活。活化的嗜酸性粒细胞引发肿瘤微环境的重大变化,包括巨噬细胞极化和肿瘤血管正常化,这些变化已知可促进肿瘤排斥。因此,我们的研究提出了癌症中嗜酸性粒细胞的新概念,可能会导致新的治疗策略。